Proffitt & Goodson’s Rigel Pharmaceuticals RIGL Stock Holding History

Proffitt & Goodson’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-174	Closed	-$6K	–	191
2018 Q3	$6K	Buy	+174	New	+$5.22K	﹤0.01%	120

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Proffitt & Goodson's RIGL Position: Q4 2018 in Review

Proffitt & Goodson sold out of Rigel Pharmaceuticals (RIGL) in Q4 2018, closing a stake of 174 shares — an estimated $6K sold.

Proffitt & Goodson first reported a position in RIGL in Q3 2018 and held it in 1 quarter. The position peaked at $6K in Q3 2018. 133 funds tracked by Wall St. Rank hold RIGL as of Q4 2018.

Proffitt & Goodson reported no remaining Rigel Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Proffitt & Goodson sold 174 Rigel Pharmaceuticals shares in Q4 2018, an estimated $6K.
Proffitt & Goodson first reported a position in Rigel Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Proffitt & Goodson's Rigel Pharmaceuticals position peaked at $6K in Q3 2018.
133 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2018.

Based on Proffitt & Goodson's 13F filing for Q4 2018, filed 22 Jan 2019.